Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female adult patients
18-60 years of age
Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)
Patients naive to MS therapy or patients switching from an FDA-approved MS therapy, including IFN-B formulations, Cop-1, Teriflunomide, and Fingolimod to BG-12
Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive
You may not be if
Primary progressive multiple sclerosis patients
Patients with previous exposure or known allergies to fumarates
MS patients switching from natalizumab, cyclophosphamide, or mitoxantrone to BG-12
Contraindications for MRI/MRS
Known presence of other neurological disorders that may mimic multiple sclerosis
Pregnancy or lactation
Requirement for chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
History of or currently active primary or secondary immunodeficiency
Active infection, or history of or known presence of recurrent or chronic infection (e.g. hepatitis B or C, HIV, syphilis, tuberculosis\_
History of progressive multifocal leukoencephalopathy
Contraindications to or intolerance of oral or intravenous (IV) corticosteroids
Clareo Health | Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
